Anebulo Pharmaceuticals
ANEB
ANEB was delisted on the 27th of February, 2026.
18 hedge funds and large institutions have $32.5M invested in Anebulo Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 2 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
11% more capital invested
Capital invested by funds: $29.4M → $32.5M (+$3.13M)
0% more funds holding
Funds holding: 18 → 18 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0.06% less ownership
Funds ownership: 55.05% → 54.99% (-0.06%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$15.8K |
| 2 |
BlackRock
New York
|
+$13.1K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13K |
| 4 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$1.74K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$344 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$41.5K |
| 2 |
HF
HRT Financial
New York
|
-$30K |
| 3 |
Millennium Management
New York
|
-$5.88K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$326 |
| 5 |
JP Morgan Chase
New York
|
-$10 |
ANEB Hedge Fund Activity: Q2 2025 in Review
18 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Anebulo Pharmaceuticals (ANEB) for Q2 2025, worth a combined $32.5M — up 11% from $29.4M a quarter earlier.
Fund positioning in ANEB was balanced in Q2 2025: 2 funds opened new positions, 2 closed out, 6 added to existing stakes and 3 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $15.8K. The largest seller was Goldman Sachs, cutting an estimated $41.5K.
- 18 institutional investors held Anebulo Pharmaceuticals (ANEB) as of Q2 2025, unchanged from Q1 2025.
- Funds reported $32.5M of Anebulo Pharmaceuticals stock for Q2 2025, up 11% quarter-over-quarter.
- 2 funds opened new Anebulo Pharmaceuticals positions in Q2 2025 and 2 closed out, a net change of 0 holders.
- The largest Anebulo Pharmaceuticals buyer in Q2 2025 was Citadel Advisors, an estimated $15.8K added.
- The largest Anebulo Pharmaceuticals seller in Q2 2025 was Goldman Sachs, an estimated $41.5K sold.
Based on aggregated 13F filings for Q2 2025.